Literature DB >> 12053100

The plasma homocysteine levels are increased in polycystic ovary syndrome.

Giuseppe Loverro1, Filomenamila Lorusso, Loredana Mei, Raffaella Depalo, Gennaro Cormio, Luigi Selvaggi.   

Abstract

Women with polycystic ovary syndrome (PCOS) have several cardiovascular disease risk factors. Since hyperhomocysteinemia is associated with early atherosclerosis, it was postulated that the homocysteine levels are higher in PCOS patients than in control subjects which, therefore, may explain the cardiovascular disease risk. Thirty-five women with PCOS and 20 healthy subjects were studied. Endocrine assays, lipid profile, homocysteine and insulin level determinations, and ultrasound evaluation were performed in all subjects. We found significantly higher mean plasma homocysteine concentrations in patients with PCOS as compared with controls (10.4 +/- 4.4 vs. 7.2 +/- 1.5 ng/dl; p < 0.003). These data show that in PCOS early atherosclerosis is not exclusively dependent on hyperinsulinemia and elevated lipid profile - PCOS patients are exposed to significantly higher homocysteine levels which might increase the cardiovascular disease risk. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053100     DOI: 10.1159/000058367

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  28 in total

1.  Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes.

Authors:  Sara R Zwart; Jesse F Gregory; Steven H Zeisel; Charles R Gibson; Thomas H Mader; Jason M Kinchen; Per M Ueland; Robert Ploutz-Snyder; Martina A Heer; Scott M Smith
Journal:  FASEB J       Date:  2015-08-27       Impact factor: 5.191

2.  Heart rate variability in young women with polycystic ovary syndrome.

Authors:  Aylin Yildirir; Funda Aybar; Giray Kabakci; Hakan Yarali; Ali Oto
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-10       Impact factor: 1.468

Review 3.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

Review 4.  Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS.

Authors:  H J Teede; S Hutchison; S Zoungas; C Meyer
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 5.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

6.  Methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdogan; Ayhan Zengi; Zuhal Eroglu; Sadik Tamsel; Murat Olukman; Fusun Saygili; Candeger Yilmaz
Journal:  Endocrine       Date:  2010-07-09       Impact factor: 3.633

7.  Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients.

Authors:  E Cakir; M Ozbek; E Ozkaya; N Colak; E Cakal; M Sayki; A Gungunes; Y Aliyazicioglu; A Mentese; T Delibasi
Journal:  J Endocrinol Invest       Date:  2010-11-16       Impact factor: 4.256

8.  Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women.

Authors:  Ayse Kargili; Feridun Karakurt; Benan Kasapoglu; Aysel Derbent; Cemile Koca; Yusuf Selcoki
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

9.  The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients.

Authors:  M Erdogan; M Karadeniz; A Berdeli; G Alper; O Caglayan; C Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

10.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.